Navigation Links
Vion Updates Conference Call Information
Date:11/4/2008

NEW HAVEN, Conn., Nov. 4 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) announced updated call information for its conference call on Thursday, November 6, 2008 to discuss its 2008 third quarter financial results.

The call will begin at 8:30 a.m. Eastern Time.

To participate in the conference call, please dial (866) 831-6270 in the U.S., ((617) 213-8858 for international callers), at least 15 minutes before the start of the call. When prompted for a pass code, please enter 85439318.

An audio webcast of the call will be accessible at http://www.vionpharm.com. Those who wish to listen to the conference call on the Web should visit the Investor Relations section of the Company's website at least 15 minutes prior to the event broadcast, and follow the instructions provided to assure that the necessary audio applications are downloaded and installed. These programs can be obtained at no charge to the user.

A replay of the call will be available two hours after the completion of the call at (888) 286-8010 in the U.S., ((617) 801-6888 for international callers), pass code 37383579. The replay will be available through Thursday, November 20, 2008.

About Vion

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Laromustine (Cloretazine(R), VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia. Clinical trials of laromustine (Cloretazine(R), VNP40101M) with cytarabine in elderly patients with acute myelogenous leukemia, with temozolomide in brain tumors, and with stem cell transplantation in advanced hematologic malignancies, are
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. AMN Healthcare Announces Third Quarter 2008 Results and Updates Full Year Guidance
2. Gonzaga Online Updates Communications Masters Program To Meet the Needs of Today's Professionals
3. SpectraScience Announces Updates
4. Vista Partners Updates Coverage on MediciNova Inc. (NASDAQ: MNOV); Maintains $8.50 Price Target
5. US Preventive Services Task Force updates prostate cancer screening recommendations
6. Sunrise Updates Date and Time of Conference Call to Discuss 2007 Financial Results and Second-Quarter 2008 Preliminary Selected Financial and Operating Data
7. Jazz Pharmaceuticals Announces Development Timeline Updates
8. Carriage Services Updates Company & Investment Profile
9. KV Pharmaceutical Company Updates Timing of Fiscal 2008 Securities and Exchange Commission Filings
10. Novadaq Updates on OPTTX Data Reported at Euroretina
11. Bioniche Updates re: Mycobacterial Cell Wall Technology Platform

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/8/2009)...t;Preventing and Healing AIDS Through Our Inner Ph...S is a result of multiple, repeated and chronic ex...essor agents, which can be either chemical, physic... Oakland, CA (PRWEB) November...ogists, physicians, chemists and other scientists ...
(Date:11/8/2009)...pharmaceuticals to be available at the Company&rsq... Toronto, ON (PRWEB) November 8, 2009... Biopharma Inc. today announced that the Company h...ical grade freeze dryer and expects to make commer...e for contract manufacturing of biopharmaceuticals...
(Date:11/8/2009)...n the Western District of Pennsylvania award a Fay... for a medical malpractice case. Attorneys Thomas...s E. Crenney and Associates, LLC handled the case ...gainst the Uniontown Hospital. The woman had to h...ge 18. , Pittsburgh, PA(P...
(Date:11/8/2009)...s won," said Dr. Charmaine Yoest. ,, WASHINGTO...240-194, the Stupak-Ellsworth-Pitts-Kaptur-Dahlkem...mandates and funding in HR 3962 passed on the Hous...esident and CEO Dr. Charmaine Yoest said, "The pas...fe Americans across this country who have flooded ...
(Date:11/8/2009)...e/ -- USAction this evening hailed passage of the ... make health care more affordable for consumers, h...ccess to health care for millions of Americans thr...and Harry Truman would be proud," said USAction Pr...mong our country,s proudest achievements. Today we...
Breaking Medicine News(10 mins):Health News:Revolutionary New Views on AIDS Highlight the Rethinking AIDS 2009 Congress; Emotional Issues can be a Significant Contributing Factor 2Health News:Revolutionary New Views on AIDS Highlight the Rethinking AIDS 2009 Congress; Emotional Issues can be a Significant Contributing Factor 3Health News:Therapure Biopharma Inc. Announces Delivery of its First Commercial-Scale Lyophilizer 2Health News:Pennsylvania Jury Awards $2.3 Million to Fayette County Woman in Medical Malpractice Case 2Health News:Americans United for Life Action Comments on Passage of Pro-Life Amendment: Bipartisan Pro-life Majority Reflects the Will of the American People 2
...ve Website For Physically Able 50+ Adults To Promo...tyle , , CABOT, Vt., May 18 If you are age 50+,...ey of health and fitness that begins in the great ... Silver Fox, log on to Cabot,s Vermont To Fabulou...
...rating Officer Promotion , , FREMONT, Calif., May...: WGBS), a leading developer of state-of-the-art g...ppointments, naming Robert J. Hariri, M.D., Ph.D.,...life science industry experience, Drs. Hariri and ...
... support program designed to improve treatment out...illers or heroin, from Reckitt Benckiser Pharmaceu...ckiser Pharmaceuticals has launched Here to Help(...oxone HCl dihydrate [2 mg/0.5 mg and 8 mg/2 mg]) C...
...e Chance to Celebrate Dad and Give Back To A Worth...e 21, children will honor father figures in their ... wire service, is helping them score a home run w...o help raise awareness for prostate cancer and rai...
... IRVINE, Calif., May 18 /PRNewswire-FirstCall/ ...02) and IDM Pharma, Inc. (Nasdaq: IDMI ) today a...lly-owned subsidiary of Takeda (Takeda America), a... wholly-owned subsidiary to effect that transactio...
...th supplements product, helps slow and repair some...ns as we age , , MIAMI, May 18 RevGenetics annou...based telomere health supplements , Astral ...represent biomarkers of human aging and disease."*...
Other Medicine News:Health News:Cabot Creamery Cooperative's 'Vermont to Vegas' Online Health and Fitness Challenge is a Virtual Blast 2Health News:Cabot Creamery Cooperative's 'Vermont to Vegas' Online Health and Fitness Challenge is a Virtual Blast 3Health News:WaferGen Appoints Seasoned Industry Executives to Board of Directors and Scientific Advisory Board 2Health News:WaferGen Appoints Seasoned Industry Executives to Board of Directors and Scientific Advisory Board 3Health News:WaferGen Appoints Seasoned Industry Executives to Board of Directors and Scientific Advisory Board 4Health News:WaferGen Appoints Seasoned Industry Executives to Board of Directors and Scientific Advisory Board 5Health News:Here to Help(TM): Unique Program Combines Direct Personal Assistance With Web-Based Resources to Improve Opioid Dependence Treatment Outcomes 2Health News:Here to Help(TM): Unique Program Combines Direct Personal Assistance With Web-Based Resources to Improve Opioid Dependence Treatment Outcomes 3Health News:Here to Help(TM): Unique Program Combines Direct Personal Assistance With Web-Based Resources to Improve Opioid Dependence Treatment Outcomes 4Health News:Here to Help(TM): Unique Program Combines Direct Personal Assistance With Web-Based Resources to Improve Opioid Dependence Treatment Outcomes 5Health News:Teleflora Hits it out of the Park With Flower Gifts for Father's Day 2Health News:Teleflora Hits it out of the Park With Flower Gifts for Father's Day 3Health News:Takeda to Acquire IDM Pharma, Adding MEPACT(R) (Mifamurtide), the First Treatment Approved for Osteosarcoma in More Than 20 Years, to Its Oncology Franchise 2Health News:Takeda to Acquire IDM Pharma, Adding MEPACT(R) (Mifamurtide), the First Treatment Approved for Osteosarcoma in More Than 20 Years, to Its Oncology Franchise 3Health News:Takeda to Acquire IDM Pharma, Adding MEPACT(R) (Mifamurtide), the First Treatment Approved for Osteosarcoma in More Than 20 Years, to Its Oncology Franchise 4Health News:Takeda to Acquire IDM Pharma, Adding MEPACT(R) (Mifamurtide), the First Treatment Approved for Osteosarcoma in More Than 20 Years, to Its Oncology Franchise 5Health News:Takeda to Acquire IDM Pharma, Adding MEPACT(R) (Mifamurtide), the First Treatment Approved for Osteosarcoma in More Than 20 Years, to Its Oncology Franchise 6Health News:RevGenetics Releases Its New Science-Based Telomere Health Supplement Formulation for DNA and Chromosome Health 2Health News:RevGenetics Releases Its New Science-Based Telomere Health Supplement Formulation for DNA and Chromosome Health 3Health News:RevGenetics Releases Its New Science-Based Telomere Health Supplement Formulation for DNA and Chromosome Health 4
(Date:11/6/2009)...ON, Ky., Nov. 6 Virtual ...I) confirmed today that the previously confirmed L...sets to Wound Management Technologies, Inc (WNDM) ...ctors and shareholders of VHGI. ,, Sharehold...l stock dividend, royalty stream and cash realized...
(Date:11/6/2009)...H TRIANGLE PARK, N.C., Nov. 6 Chim...orally-available antiviral therapeutics to address...he development of the company,s lead antiviral com...HO) and the Global Health Security Initiative (GHS...ing developed for the treatment of smallpox, as we...
(Date:11/6/2009)...GO, Nov. 6 California American Wat..."No Drugs Down the Drain" week for its San Diego C...sponsored by public and private agencies alike tow...pollution in our source water supplies. ,, Cali... are encouraged to drop off expired or unwanted ph...
Breaking Medicine Technology:OTCBB-VHGI Updates Shareholders on Status of Healthcare Asset Sale and Treasure Gulch Gold Mine Development Strategy 2OTCBB-VHGI Updates Shareholders on Status of Healthcare Asset Sale and Treasure Gulch Gold Mine Development Strategy 3OTCBB-VHGI Updates Shareholders on Status of Healthcare Asset Sale and Treasure Gulch Gold Mine Development Strategy 4Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox 2Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox 3California American Water Celebrates 'No Drugs Down the Drain' Week in San Diego 2Meat Dairy Wont Up Odds for Breast Cancer 55638 1Meat Dairy Wont Up Odds for Breast Cancer 55638 2Meat Dairy Wont Up Odds for Breast Cancer 55638 3WDIV TV Blue Cross Blue Shield of Michigan and The Parade Company Help Launch The Biggest Loser 3A Detroit Edition 55634 1WDIV TV Blue Cross Blue Shield of Michigan and The Parade Company Help Launch The Biggest Loser 3A Detroit Edition 55634 2Acoustic tweezers can position tiny objects 9729 1Acoustic tweezers can position tiny objects 9729 2Acoustic tweezers can position tiny objects 9729 3
... study, called POLI 1 -, BOSTON, Nov. 2 R1626, o...c hepatitis C virus (HCV) infection, has,shown pro...n with,PEGASYS(R) (peginterferon alfa-2a) and COPE...esented at the American Association for the Study ...n Boston, Nov. 2-6. After four,weeks of treatment ...
...mprove,significantly the safety and well-being of ...ency medical information service, has joined,the A...,s research and,support, to offer MedicAlert(R) + ...illion Americans living with Alzheimer,s and almos...mer,s or another dementia. (Photo: http://www.ne...
Other Medicine Technology:Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks 2Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks 3Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks 4Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks 5Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks 6Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks 7MedicAlert Foundation Joins The Alzheimer's Association to Offer MedicAlert(R) + Alzheimer's Association Safe Return(R) - Live 24-Hour Emergency Response for Wandering and Medical Emergencies 2MedicAlert Foundation Joins The Alzheimer's Association to Offer MedicAlert(R) + Alzheimer's Association Safe Return(R) - Live 24-Hour Emergency Response for Wandering and Medical Emergencies 3
Maverick Over-The-Wire 9 mm Catheter
CT100 Contact Tonometer
...ASURABLE ROI - Our networked solutions are deliver...cardiology. Never purchase software upgrades again...s to meet the ever-changing needs of your healthca...iology departments have a mix of old and new equip...
...X for Cardiology is the first digital solution des...us modalities both within and outside cardiology. ...chival solutions, Agfas combined expertise in both...r customers to work the way they want, wherever th...
Medicine Products: